Ocular Therapeutix, Inc.

Day range

$6.40 – $6.62

Open

$6.50

Prev close

$6.50

Volume

930.27K

Market cap

$1.43B

Shares out

219.62M

P/E

—

P/S

27.42

P/B

2.74

P/FCF

—

ROE

-58.0%

ROA

-44.9%

Debt/Equity

0.14

Div yield

0.00%

As of Oct 23, 2026

• Executive officer departureOct 16, 2026

  On October 14, 2026, Sanjay Nayak, M.B.B.S., Ph.D., Chief Strategy Officer of Ocular Therapeutix, Inc. (the "Company"), notified the Company of his resignation from the Company, effective October 16, 2026, to become the Chief Executive Officer of a privately-held company.

• Executive compensation changeJun 12, 2026

  Additionally, the Company granted Mr. Robins, effective June 10, 2026 (the 'Grant Date'), (i) a stock option to purchase up to 14,024 shares of the Company's common stock at a per share exercise price equal to the closing price of the Company's common stock on The Nasdaq Global Market on the Grant Date and (ii) a restricted stock unit award representing the right to receive 15,441 shares of the Company's common stock. Subject to Mr. Robins' continued service to the Company, his option award vests in equal monthly installments over a four-year period, and his restricted stock unit award vests in equal yearly installments over a three-year period.

• Investor presentationFeb 27, 2026

  Ocular Therapeutix, Inc. (the "Company") will make available under the Investors section of its corporate website the slides to be presented by the Company at the 49th Macula Society Annual Meeting on February 27, 2026

• Equity compensation grantJan 23, 2026

  In connection with his appointment as interim Chief Financial Officer, on the Robins Effective Date, Mr. Robins was granted an option to purchase an aggregate of 33,000 shares of the Company's common stock at an exercise price of $11.45 per share, the closing sale price (for the primary trading session) of the Company's common stock on the Nasdaq Global Market on the Robins Effective Date. The stock option vests and becomes exercisable over four years in equal monthly installments until the fourth anniversary of the grant date, subject to the terms and conditions of the Company's 2021 Stock Incentive Plan, as amended.

• Underwriting agreementSep 30, 2025

  On September 30, 2025, Ocular Therapeutix, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with BofA Securities, Inc., TD Securities (USA) LLC and Piper Sandler & Co., as representatives of the several underwriters named therein (the "Underwriters"), relating to an underwritten offering (the "Offering") of 37,909,018 shares. The Underwriting Agreement contains customary representations, warranties, covenants and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions.

Days to cover

7.3

Short interest

29.41M

Avg volume

4.06M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Diabetic Retinopathy Pipeline Insight 2026: Comprehensive Analysis of 50+ Companies and 55+ Drugs in Development
  positiveGlobeNewswire Inc.· Jul 3, 2026
• Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences
  positiveGlobeNewswire Inc.· Jul 1, 2026
• Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
  positiveThe Motley Fool· Jun 15, 2026
• What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors
  negativeThe Motley Fool· May 19, 2026
• Ocular Therapeutix™ to Host Investor Day on June 17, 2026
  positiveGlobeNewswire Inc.· Apr 22, 2026